Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio SEC filings document the former FibroGen public-company record, including the completed 2026 name change and common-stock ticker transition from FGEN to KYNB. Material-event reports cover operating results, clinical and regulatory disclosures for FG-3246, FG-3180 and roxadustat, capital-structure matters, Nasdaq continued-listing compliance notices, and the completed sale of FibroGen International (Hong Kong) Ltd. and related pro forma financial information.
Proxy materials address shareholder voting matters, board and governance practices, executive compensation, equity awards and related corporate-control disclosures. The filing record also includes formal amendments to organizational documents and other 8-K disclosures tied to the company’s biopharmaceutical development focus and corporate transformation.